[1]肖蓉雪,汪谞,郜俊清,等.药物洗脱支架联合药物涂层球囊在冠状动脉左主干分叉病变中的应用[J].介入放射学杂志,2020,29(04):350-354.
 XIAO Rongxue,WANG Xu,GAO Junqing,et al.The application of drug-eluting stent combined with drug coated balloon in treating coronary lesions located at left main bifurcation site[J].journal interventional radiology,2020,29(04):350-354.
点击复制

药物洗脱支架联合药物涂层球囊在冠状动脉左主干分叉病变中的应用()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年04
页码:
350-354
栏目:
心脏介入
出版日期:
2020-05-08

文章信息/Info

Title:
The application of drug-eluting stent combined with drug coated balloon in treating coronary lesions located at left main bifurcation site
作者:
肖蓉雪汪谞郜俊清刘宗军
Author(s):
XIAO Rongxue WANG Xu GAO Junqing LIU Zongjun.
Department of Cardiology, Shanghai Putuo District Central Hospital, Shanghai 200062, China
关键词:
【关键词】 左主干分叉病变药物涂层球囊药物洗脱支架
文献标志码:
A
摘要:
【摘要】 目的?评价药物洗脱支架(DES)联合药物涂层球囊(DCB)治疗冠状动脉左主干(LM)分叉病变的临床效果。方法?回顾性分析2016年7月至2017年7月采用DES联合DCB治疗的8例LM分叉病变患者临床资料。8例患者均接受LM和左前降支病变处DES治疗,左回旋支开口处DCB治疗,其中6例手术在血管内超声导引下进行。术后即刻造影评价病变血管通畅情况,术后6个月随访再狭窄率及6个月内严重临床事件发生率。结果?DES联合DCB治疗LM分叉病变再狭窄率低[LM(8.4±5.3)%,左前降支(18.2±5.0)%, 左回旋支(30.5±16.5)%]。术后所有患者未发生严重临床事件。结论? DES联合DCB介入治疗LM分叉病变安全有效。

参考文献/References:

[1] Dash D. Stenting of left main coronary artery stenosis: A to Z[J]. Heart Asia, 2013, 5: 18-27.
[2] Lee PH, Ahn JM, Chang M, et al. Left main coronary artery disease: secular trends in patient characteristics, treatments, and outcomes[J]. J Am Coll Cardiol, 2016, 68: 1233-1246.
[3] De Rosa S, Polimeni A, Sabatino J, et al. Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis[J]. BMC Cardiovasc Disord, 2017, 17: 240.
[4] Takagi H, Ando T, Umemoto T, et al. Drug-eluting stents versus coronary artery bypass grafting for left-main coronary artery disease[J]. Catheter Cardiovasc Interv, 2018, 91: 697-709.
[5] Colombo A, Bramucci E, Sacca S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study[J]. Circulation, 2009, 119: 71-78.
[6] Sato K, Naganuma T, Costopoulos C, et al. Calcification analysis by intravascular ultrasound to define a predictor of left circumflex narrowing after cross-over stenting for unprotected left main bifurcation lesions[J]. Cardiovasc Revasc Med, 2014, 15: 80-85.
[7] Niemela M, Kervinen K, Erglis A, et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the nordic-baltic bifurcation studyⅢ[J]. Circulation, 2011, 123: 79-86.
[8] 刘晓哲, 王?兵,刘俊超, 等. 药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用[J]. 介入放射学杂志, 2018, 27:410-414.
[9] Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J]. Eur J Cardiothorac Surg, 2014, 46: 517-592.
[10] 闫?冰,姚?芳, 刘凯悦, 等. 按必要性支架植入术原则应用药物洗脱支架和药物涂层球囊治疗冠状动脉分叉病变的有效性和安全性[J]. 中国老年学杂志, 2016, 36:3423-3425.
[11] Naganuma T, Latib A, Sgueglia GA, et al. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study[J]. Int J Cardiol, 2015, 184: 17-21.
[12] Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis[J]. Lancet, 2015, 386: 655-664.
[13] Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery[J]. Circulation, 2002, 106: 698-702.
[14] Tamburino C, Di Salvo ME, Capodanno D, et al. Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes[J]. Am J Cardiol, 2009, 103: 187-193.
[15] Tamburino C, Di Salvo ME, Capodanno D, et al. Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry[J]. Eur Heart J, 2009, 30: 1171-1179.
[16] Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study[J]. J Am Coll Cardiol, 2008, 52: 1134-1140.
[17] Cassese S, Kufner S, Xhepa E, et al. Three-year efficacy and safety of new-versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials[J]. Clin Res Cardiol, 2016, 105: 575-584.
[18] Kobayashi N, Ito Y, Yamawaki M, et al. Differences between first-generation and second-generation drug-eluting stent regarding in-stent neoatherosclerosis characteristics: an optical coherence tomography analysis[J]. Int J Cardiovasc Imaging, 2018, 34: 1521-1528.
[19] Ajayi NO, Lazarus L, Vanker EA, et al. The impact of left main coronary artery morphology on the distribution of atherosclerotic lesions in its branches[J]. Folia Morphol (Praha), 2013, 72: 197-201.
[20] Tamburino C, Capranzano P, Capodanno D, et al. Plaque distribution patterns in distal left main coronary artery to predict outcomes after stent implantation[J]. JACC Cardiovasc Interv, 2010, 3: 624-631.
[21] Vassilev D, Mateev H, Alexandrov A, et al. Double bifurcation optimization stent system technique for left main stenosis[J]. J Interv Cardiol, 2014, 27: 570-573.
[22] Chieffo A, Hildick-Smith D. The European Bifurcation Club Left Main Study (EBC MAIN): rationale and design of an international, multicentre, randomised comparison of two stent strategies for the treatment of left main coronary bifurcation disease[J]. EuroIntervention, 2016, 12: 47-52.
[23] Hikichi Y, Umezu M, Node K, et al. Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model[J]. Cardiovasc Interv Ther, 2017, 32: 12-17.
[24] Wang Y, Mintz GS, Gu Z, et al. Meta-analysis and systematic review of intravascular ultrasound versus angiography-guided drug eluting stent implantation in left main coronary disease in 4592 patients[J]. BMC Cardiovasc Disord, 2018, 18: 115.
[25] Liu XM, Yang ZM, Liu XK, et al. Intravascular ultrasound-guided drug-eluting stent implantation for patients with unprotected left main coronary artery lesions: a single-center randomized trial[J]. Anatol J Cardiol, 2019, 21: 83-90.
[26] Palmerini T, Alessi L, Rizzo N, et al. Percutaneous revascularization of left main: role of imaging, techniques, and adjunct pharmacology[J]. Catheter Cardiovasc Interv, 2012, 79: 990-999.
[27] 张成超, 谷涌泉, 齐立行, 等. 药物涂层球囊扩张成形术治疗颈动脉支架内再狭窄2例[J]. 介入放射学杂志, 2019, 28:159-161.
[28] El Amrawy AM, Leon-Jimenez J, Camacho-Freire SJ, et al. Long term efficacy of drug coated balloon for radial artery angioplasty[J]. Cardiol J, 2018, 25: 743-744.
[29] Qiu J, Han ZY, Wang X, et al. Outcomes of patients treated with drug-coated balloons for de novo large coronary vessels[J]. Zhonghua Xin Xue Guan Bing Za Zhi,2019,47: 452-456
[30] Liu Y, Zhang YJ, Deng LX, et al. 12-month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding
3.0 mm[J]. Int J Cardiovasc Imaging, 2019, 35: 579-586.

相似文献/References:

[1]谷涌泉,郭建明,崔世军,等.激光消融联合药物涂层球囊成形治疗椎动脉支架重度再狭窄1例 [J].介入放射学杂志,2018,27(10):1001.
 GU Yongquan,GUO Jianming,CUI Shijun,et al.Laser ablation combined with drug- coating balloon angioplasty for the treatment of severe restenosis of vertebral artery stent: report of one case[J].journal interventional radiology,2018,27(04):1001.

备注/Memo

备注/Memo:
(收稿日期:2019-06-24)
(本文编辑:边?佶)
更新日期/Last Update: 2020-05-06